A ready-to-use formulation of Caldolor (ibuprofen injection) has been made available by Cumberland Pharmaceuticals.
Caldolor, a nonsteroidal antiinflammatory drug, is indicated for use in adults and pediatric patients 6 months and older for the management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics. It is also approved for the reduction of fever.
Each premixed bag contains 800mg of ibuprofen in a 200mL low sodium formulation for injection and is intended for 800mg doses only. In addition to the ready-to-use presentation, Caldolor continues to be available in 800mg/8mL single-dose vials for dilution.
In addition to the new formulation, Cumberland announced that data from a study evaluating the intravenous therapy in pediatric patients less than 6 months of age would be forthcoming. The Company received approval to extend the use of Caldolor to pediatric patients 6 months of age and older in 2015.
For more information visit cumberlandpharma.com.
This article originally appeared on MPR